TRT and Cardiovascular Events: What the Secondary-Hypogonadism Cohort Actually Found

Why this matters

You sit in the waiting room reading the discharge summary for the third time. Low testosterone. Pituitary adenoma. The word "replacement" sounds simple enough until you search it at 2am and the first result mentions heart attacks, strokes, and blood clots. Now you are sitting across from a urologist or endocrinologist who says "we should start you on TRT" and all you can hear is the alarm bell that someone on a forum rang at full volume last night.

This is the scenario that built this audience. You are not a hypochondriac. You are the guy whose labs came back "normal" for years while you felt like you were aging at double speed. Low motivation, disappearing muscle, brain fog that made you question whether you were still sharp enough for your job. You finally found a doctor who checked the right labs and said your pituitary was the problem. You thought the hard part was over. Now the prescription pad comes out and the doctor says "testosterone" and the relief collides with a fear you cannot quite name.

The fear is cardiovascular. It is the single most common reason men hesitate on TRT or abandon it within the first six months. It is the reason some doctors refuse to prescribe at all, even when the deficiency is organic and well-documented. And it is the reason this audience exists: the gap between what the data actually shows and what the loud voices on both sides say. One camp treats TRT like a heart attack in a syringe. The other treats it like a fountain of youth with no downside. Neither is honest.

What you need is the middle ground. You need to know what a real cohort of men with the same condition you have actually experienced on TRT over years of follow-up, not a one-line summary from a supplement company or a cautionary tale from someone who never had a pituitary tumor. This article exists because a recent study finally looked at that specific question: men with secondary hypogonadism from pituitary tumors, on or off TRT, followed for nearly a decade. The results are not what the headline writers expected.

Mechanism / what the research actually shows

The study is Munro et al., published in the Journal of Clinical Endocrinology and Metabolism (PMID 41252267). It used the Halifax Neuropituitary registry, a prospectively maintained database tracking every neuropituitary patient in Nova Scotia from 2006 through 2023. That registry structure matters: it means follow-up was structured and standardized, not pieced together from scattered records.

The cohort was 408 men with at least one year of follow-up. 278 had nonfunctioning pituitary adenomas (NFPA) and 130 had prolactinomas. Of those, 258 had secondary hypogonadism, meaning their pituitary damage was severe enough to suppress testosterone production. 44 of those men, about 17%, were not treated with TRT. The rest received either intramuscular or transdermal testosterone.

The primary endpoint was MACE: major adverse cardiovascular events, defined as nonfatal myocardial infarction, nonfatal stroke, coronary revascularization without MI, or cardiac-specific mortality. Median follow-up was 8.1 years, which is substantial in a field where most TRT studies run for months, not nearly a decade.

Here is what they found. 73 men (17.9%) experienced a MACE during follow-up. Crude event rates were not significantly different across the three groups (TRT-treated, untreated hypogonadism, and no hypogonadism). When the researchers ran multivariable models adjusting for traditional cardiovascular risk factors like age, diabetes, smoking, dyslipidemia, hypertension, and pre-existing cardiovascular disease, TRT-treated secondary hypogonadism was not associated with higher odds of MACE compared to men without hypogonadism at all (OR 0.74, 95% CI 0.37 to 1.51).

The critical finding came from competing-risk models, which account for the fact that men can die of non-cardiovascular causes before ever having a cardiac event. After adjusting for age, pre-existing cardiovascular disease, statin use, and antihypertensive use, TRT-treated men with secondary hypogonadism had a significantly LOWER risk of MACE compared to men without hypogonadism (subdistribution hazard ratio 0.45, 95% CI 0.24 to 0.85, P = .013). That is not a typo. TRT was associated with roughly half the cardiovascular event risk, not double it.

What drove MACE was not testosterone. It was the usual suspects: age, diabetes, smoking, dyslipidemia, hypertension, and pre-existing cardiovascular disease. Testosterone levels and TRT treatment status were not independent predictors.

There is a signal worth noting. Non-cardiac deaths were highest in the untreated hypogonadism group: 20.5% versus 6.5% in TRT-treated men and 3.3% in men without hypogonadism. The untreated men were also older and had more pre-existing cardiovascular disease at baseline, which is why the study authors frame this as hypothesis-generating rather than conclusive proof that TRT prevents death.

The limitations are honest. The study was retrospective and non-randomized, restricted to men with pituitary tumors, and potentially underpowered for subgroup analyses. It cannot prove causation. But it directly addresses the population that matters to this audience, and it found no signal of cardiovascular harm from TRT. If anything, it found the opposite.

The protocol

If you have secondary hypogonadism and are starting or continuing TRT, the cardiovascular question is not whether to proceed. The evidence supports proceeding. The question is how to monitor so you catch problems early and can distinguish real signals from noise. Here is what that looks like in practice.

Before your first dose, get a baseline cardiovascular risk panel. That means a full lipid panel (total cholesterol, LDL, HDL, triglycerides), fasting glucose or HbA1c, blood pressure measured on three separate days, and a baseline ECG if you are over 40 or have any cardiac history. Check hematocrit and hemoglobin. If hematocrit is already above 50 percent, address that before starting testosterone. Get a PSA if you are over 40. Check LH and FSH to confirm the secondary pattern (low or inappropriately normal LH with low testosterone). Check prolactin to rule out a prolactinoma as the driver. These are not optional add-ons. They are the floor.

During the first three months, recheck hematocrit at 6 weeks and again at 3 months. TRT stimulates erythropoiesis, and a hematocrit above 54 percent is the threshold where you act. Your options are reducing dose, switching from intramuscular to transdermal (which tends to cause less polycythemia), or therapeutic phlebotomy if the number is climbing fast. Check blood pressure at each visit. If it was normal at baseline and is now consistently above 130/85, that is a signal to address through dose adjustment, not abandonment of treatment. Recheck total and free testosterone at 6 weeks to confirm you are in the target range. Check estradiol with a sensitive assay, because aromatization in secondary hypogonadism can be unpredictable.

At six months and then annually, repeat the full lipid panel and fasting glucose or HbA1c. TRT can shift HDL downward and hematocrit upward. The magnitude matters less than the trajectory. If LDL rises more than 20 mg/dL from baseline, that warrants a conversation about statin therapy or dose adjustment, not panic. Recheck hematocrit every 6 months once stable. PSA annually if over 40. Recheck LH and FSH annually to confirm continued suppression, which confirms the replacement is adequate and the axis has not recovered.

The cardiovascular risk factors that actually matter are not testosterone. The Munro study found that what predicted MACE was age, diabetes, smoking, dyslipidemia, hypertension, and pre-existing cardiovascular disease. Your protocol should treat those aggressively regardless of TRT status. If you are on TRT and your diabetes is uncontrolled, your lipids are untreated, and your blood pressure is 150/95, testosterone is not your problem. Fix the foundations.

Request a cardiology referral if you have two or more cardiovascular risk factors (hypertension, dyslipidemia, diabetes, smoking, family history of premature coronary artery disease), if you develop exertional chest pain or new shortness of breath on TRT, or if your baseline ECG shows anything abnormal. A cardiologist who understands TRT in the context of hypogonadism is worth finding. One who dismisses all testosterone as dangerous is not useful to you.

On dosing: the men in the Halifax cohort received standard replacement doses, either intramuscular or transdermal, not bodybuilding protocols. If your total testosterone on therapy is running above 1000 ng/dL, you are outside the evidence base. Target the mid-normal range, roughly 500 to 800 ng/dL, and let symptoms guide fine-tuning within that band. More is not better. More is just more, and it raises the hematocrit and lipid risks that the replacement-dose data does not fully capture.

Caveats and when to escalate

The Munro study is the best available evidence for men with secondary hypogonadism from pituitary tumors, but it is not a blank check. Understanding its limits is what separates evidence-based practice from zealotry.

The cohort was men with nonfunctioning pituitary adenomas and prolactinomas, organic structural causes of secondary hypogonadism. If your low testosterone is age-related decline, obesity-driven suppression, or primary gonadal failure (Klinefelter syndrome, orchitis, chemotherapy damage), this study does not directly apply to you. The cardiovascular risk profile of a 55-year-old with metabolic syndrome and low testosterone is different from a 35-year-old with a pituitary tumor and low testosterone. Do not conflate them. The mechanisms are different and the risk-benefit calculus is different.

The study was retrospective and non-randomized. It observed what happened to men who were or were not treated with TRT. It did not assign treatment. The untreated group was older and had more pre-existing cardiovascular disease at baseline, which means the apparent survival advantage of TRT-treated men may partly reflect selection bias. The competing-risk model finding (subdistribution hazard ratio 0.45) is hypothesis-generating, not proof that TRT prevents cardiovascular events. It says that in this population, TRT was not associated with harm. That is not the same as proven protection.

Everything in this article applies to replacement-level testosterone. If you are running cycles at bodybuilding doses, the cardiovascular literature is unambiguous: supraphysiologic testosterone increases left ventricular mass, worsens lipid profiles, and raises hematocrit to dangerous levels. The Munro data does not exonerate that practice and was never intended to.

On medication interactions, testosterone can potentiate the effects of warfarin and other anticoagulants. Monitor INR more frequently if you are on both. It can alter insulin sensitivity, sometimes improving it but occasionally requiring diabetes medication adjustments. If you are on chronic oral corticosteroids, that suppresses the HPG axis independently and complicates the diagnostic picture. If you are on opioids chronically, including long-term pain management, those also suppress gonadotropin release and may be contributing to the hypogonadism you are treating.

If your treating physician cannot interpret a lipid panel, does not check hematocrit, or refuses to engage with the cardiovascular literature beyond either dismissing all risk or refusing to prescribe, find a new prescriber. Endocrinologists with pituitary expertise are the right specialists for secondary hypogonadism. Urologists who only treat primary hypogonadism may not have the full picture.

And if you develop chest pain, especially exertional, palpitations with lightheadedness, calf pain or swelling suggesting DVT, sudden visual changes, or focal neurological symptoms, those are not TRT side effects to manage at your next appointment. Those are emergency department presentations. Call 911. None of this evidence changes that.

This article is educational and is not medical advice. Testosterone replacement therapy is a prescription treatment that must be managed by a qualified physician with appropriate lab monitoring. If you experience chest pain, shortness of breath, or other emergency symptoms, call 911.